James R. Kasinger

2021

In 2021, James R. Kasinger earned a total compensation of $4.6M as General Counsel at CRISPR Therapeutics AG, a 79% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$229,500
Option Awards$2,771,741
Salary$425,000
Stock Awards$1,204,920
Other$11,600
Total$4,642,761

Kasinger received $2.8M in option awards, accounting for 60% of the total pay in 2021.

Kasinger also received $229.5K in non-equity incentive plan, $425K in salary, $1.2M in stock awards and $11.6K in other compensation.

Rankings

In 2021, James R. Kasinger's compensation ranked 2,849th out of 12,412 executives tracked by ExecPay. In other words, Kasinger earned more than 77.0% of executives.

ClassificationRankingPercentile
All
2,849
out of 12,412
77th
Division
Manufacturing
1,131
out of 5,498
79th
Major group
Chemicals And Allied Products
449
out of 2,374
81st
Industry group
Drugs
393
out of 2,095
81st
Industry
Biological Products, Except Diagnostic Substances
115
out of 452
75th
Source: SEC filing on April 25, 2022.

Kasinger's colleagues

We found five more compensation records of executives who worked with James R. Kasinger at CRISPR Therapeutics AG in 2021.

2021

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2021

Brendan Smith

CRISPR Therapeutics AG

Chief Financial Officer

2021

Tony Ho

CRISPR Therapeutics AG

Former EVP, Research and Development

2021

Lawrence Klein

CRISPR Therapeutics AG

Chief Operating Officer

2021

Michael Tomsicek

CRISPR Therapeutics AG

Chief Financial Officer

News

In-depth

You may also like